SCHEMBL3394523

SCHEMBL3394523

CCCCCCCCCCCCCCCCCCN(CCCCCCCCCCCCCCCCCC)CC(=O)NCCCNCCCCNCCCN

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC6A5 Q9Y345 2/20 0.47
RELA Q04206 4/20 0.46
CASP2 P42575 1/20 0.45
NAAA Q02083 1/20 0.43
PAOX Q6QHF9 1/20 0.43
GNAI3 P08754 1/20 0.43
GNAO1 P09471 1/20 0.43
GNAI1 P63096 1/20 0.43
DNM1 Q05193 1/20 0.42
GRIA1 P42261 1/20 0.42
RRM1 P23921 1/20 0.41
KDM4A O75164 1/20 0.41
HIF1A Q16665 1/20 0.41
TET2 Q6N021 1/20 0.41
DOHH Q9BU89 1/20 0.41
EPHX1 P07099 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1037232 1.00 SLC6A5 (0.47) SLC6A5RELACASP2NAAAPAOX
SCHEMBL8723696 0.91 SLC6A5 (0.55) SLC6A5CASP2NAAAPAOXGNAI3
SCHEMBL27971595 0.88 SLC6A5 (0.46) SLC6A5RELACASP2NAAAPAOX
SCHEMBL27817058 0.88 SLC6A5 (0.46) SLC6A5RELACASP2NAAAPAOX
SCHEMBL28264890 0.88 SLC6A5 (0.46) SLC6A5RELACASP2NAAAPAOX
SCHEMBL27490298 0.88 SLC6A5 (0.46) SLC6A5RELACASP2NAAAPAOX
SCHEMBL9290507 0.87 NAAA (0.50) CASP2NAAAPAOXDNM1EPHX1
SCHEMBL19040774 0.87 CASP2 (0.58) CASP2NAAADNM1EPHX1
SCHEMBL28817375 0.86 SLC6A5 (0.47) SLC6A5RELACASP2NAAAPAOX
SCHEMBL28093185 0.86 SLC6A5 (0.47) SLC6A5RELACASP2NAAAPAOX

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4674431-A1 LIPID NANOPARTICLES, PHARMACEUTICAL COMPOSITION, AND PRODUCTION METHOD FOR LIPID NANOPARTICLES Japan Science and Technology Agency (JP) 2026-01-07 EP disclosed
WO-2024181580-A1 LIPID NANOPARTICLES, PHARMACEUTICAL COMPOSITION, AND PRODUCTION METHOD FOR LIPID NANOPARTICLES 国立研究開発法人科学技術振興機構 2024-09-06 WO disclosed
EP-1812074-B1 INTRACELLULAR PEPTIDE DELIVERY NITTO DENKO CORP (JP) 2010-12-29 EP disclosed
US-20100297023-A1 Lipid IMUTHES LIMITED UNIVERSITY OF THE WITWATERSRAND 2010-11-25 US disclosed
EP-2124895-A2 LIPIDS AND THEIR USE AS NON-VIRAL DELIVERY VEHICLE IMUTHES LIMITED (GB) 2009-12-02 EP disclosed
WO-2008078102-A2 LIPIDS AND THEIR USE AS NON-VIRAL DELIVERY VEHICLE IMUTHES LIMITED (GB) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297023-A1 Lipid NR1H2, NR1H3, NR1H4 SLC6A5 1426/4885RELA 3385/4885CASP2 2631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.